Compare SNGX & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | VVOS |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.5M |
| IPO Year | 2006 | 2020 |
| Metric | SNGX | VVOS |
|---|---|---|
| Price | $0.38 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $6.00 | $2.75 |
| AVG Volume (30 Days) | ★ 334.0K | 151.7K |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | 6.76 |
| EPS | ★ N/A | N/A |
| Revenue | $119,371.00 | ★ $17,443,000.00 |
| Revenue This Year | N/A | $69.66 |
| Revenue Next Year | N/A | $48.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.05 |
| 52 Week Low | $0.28 | $0.36 |
| 52 Week High | $6.23 | $5.21 |
| Indicator | SNGX | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 38.04 |
| Support Level | $0.37 | $0.37 |
| Resistance Level | $0.38 | $0.55 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 71.54 | 48.17 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.